Author: Cantargia

Posted Date:

May 6, 2026

Invitation to the Presentation of Cantargia’s Interim Report for Q1 2026

Cantargia

May 6, 2026
Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML

Cantargia

April 27, 2026
Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC

Cantargia

April 17, 2026
Notice of Annual General Meeting in Cantargia AB (publ)

Cantargia

April 17, 2026
Cantargia Publishes Annual Report 2025

Cantargia

April 17, 2026
New Preclinical Data on Anti-Tumor Effects of Nadunolimab in Metastatic Colorectal Cancer Presented at the Keystone Cancer Immunotherapy Conference

Cantargia

March 18, 2026
Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference

Cantargia

March 5, 2026
Cantargia to Participate in TD Cowen’s Annual Healthcare Conference

Cantargia

February 23, 2026
Cantargia Publishes Full Year Report 2025

Cantargia

February 20, 2026
Invitation to the Presentation of Cantargia’s Annual Results for 2025

Cantargia

February 8, 2026